Literature DB >> 7751427

Effects of food on the bioequivalence of different verapamil sustained-release formulations.

S A Waldman1, J Morganroth.   

Abstract

Previously, clinical studies comparing generic and reference formulations of sustained-release (SR) verapamil tablets revealed significant increases in the PR interval in subjects given the generic formulation in the presence of food. To determine the mechanisms underlying these differences in pharmacodynamics, the present analyses examined the pharmacokinetics of these formulations in the presence and absence of food. After single or multiple doses in fasting subjects, AUCs, Cmaxs, and tmaxs were similar, suggesting that these formulations were bioequivalent in the fasted state. However, the generic formulation exhibited a higher AUC(0-6) in fed subjects, suggesting that this formulation may be absorbed more rapidly than the reference formulation when given with food. Analysis of AUC(0-6) showed that 34% of the subjects receiving the generic formulation exhibited rapid absorption, compared with only 8% receiving the reference formulation. Significant increases in the PR interval were seen in nine fed subjects receiving the generic formulation compared with two receiving the reference formulation. Similarly, three fed subjects receiving the generic drug who were rapid absorbers exhibited first-degree heart block, whereas this conduction disturbance was seen in only one fed subject receiving the reference formulation. Thus, increased conduction disturbances seen in subjects given the generic formulation with a meal likely reflect more rapid absorption of this formulation in the presence of food, resulting in an increase in the ratio of more potent to less potent enantiomers of verapamil in the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751427     DOI: 10.1002/j.1552-4604.1995.tb05006.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

Review 1.  [Original brands and generic preparations].

Authors:  K U Petersen
Journal:  Med Klin (Munich)       Date:  2000-01-15

Review 2.  Generic drugs. Therapeutic equivalence.

Authors:  P A Meredith
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 3.  Bioequivalence of controlled-release calcium antagonists.

Authors:  R Schall; F R Müller; F O Müller; H G Luus
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

4.  Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.

Authors:  Gayatri Sathyan; Roger R Dmochowski; Rodney A Appell; Cindy Guo; Suneel K Gupta
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.

Authors:  B S Schug; E Brendel; E Chantraine; D Wolf; W Martin; R Schall; H H Blume
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

Review 6.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 7.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272

Review 8.  Generic versus brand-name drugs used in cardiovascular diseases.

Authors:  Lamberto Manzoli; Maria Elena Flacco; Stefania Boccia; Elvira D'Andrea; Nikola Panic; Carolina Marzuillo; Roberta Siliquini; Walter Ricciardi; Paolo Villari; John P A Ioannidis
Journal:  Eur J Epidemiol       Date:  2015-11-30       Impact factor: 8.082

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.